Tech Company Financing Transactions

Arch Oncology Funding Round

Arch Oncology closed a $105 million Series C funding round on 4/28/2021. Backers included 3x5 Partners, Cowen Capital Partners and Eventide Asset Management.

Transaction Overview

Company Name
Arch Oncology
Announced On
4/28/2021
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series C
Investors

3x5 Partners (Lead Investor) (Joseph Biller)

Cowen Capital Partners (Lead Investor) (Eric Pham)

Eventide Asset Management (Lead Investor) (Joy Ghosh)

Adage Capital Management

Avego Healthcare Capital

Broadfin Capital

FMB Research

Lightchain

Point72 Ventures

RiverVest Venture Partners (John McKearn)

Roche Venture Fund

Proceeds Purpose
This financing enables the clinical progress of our differentiated anti-CD47 product candidate AO-176, currently in Phase 1/2 clinical trials for solid tumors, both as a monotherapy and in combination with paclitaxel, and multiple myeloma.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2000 Sierra Point Pkwy. 700
Brisbane, CA 94005
USA
Phone
Undisclosed
Website
www.archoncology.com
Email Address
[email protected]
Overview
Arch Oncology is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Profile
Arch Oncology LinkedIn Company Profile
Social Media
Arch Oncology Company Twitter Account
Company News
Arch Oncology News
Facebook
Arch Oncology on Facebook
YouTube
Arch Oncology on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Laurence Blumberg
  Laurence Blumberg LinkedIn Profile  Laurence Blumberg Twitter Account  Laurence Blumberg News  Laurence Blumberg on Facebook
Chief Medical Officer
Jackie Walling
  Jackie Walling LinkedIn Profile  Jackie Walling Twitter Account  Jackie Walling News  Jackie Walling on Facebook
Chief Operating Officer
Ronald Krasnow
  Ronald Krasnow LinkedIn Profile  Ronald Krasnow Twitter Account  Ronald Krasnow News  Ronald Krasnow on Facebook
Chief Scientific Officer
Daniel Pereira
  Daniel Pereira LinkedIn Profile  Daniel Pereira Twitter Account  Daniel Pereira News  Daniel Pereira on Facebook
Vice President
Vicki Sung
  Vicki Sung LinkedIn Profile  Vicki Sung Twitter Account  Vicki Sung News  Vicki Sung on Facebook
VP - Finance
Galit Yaakobovitz
  Galit Yaakobovitz LinkedIn Profile  Galit Yaakobovitz Twitter Account  Galit Yaakobovitz News  Galit Yaakobovitz on Facebook
VP - Operations
Kevin Romanko
  Kevin Romanko LinkedIn Profile  Kevin Romanko Twitter Account  Kevin Romanko News  Kevin Romanko on Facebook
VP - R & D
Arun Kashyap
  Arun Kashyap LinkedIn Profile  Arun Kashyap Twitter Account  Arun Kashyap News  Arun Kashyap on Facebook
VP - Regulatory Affairs
Michele DeVries
  Michele DeVries LinkedIn Profile  Michele DeVries Twitter Account  Michele DeVries News  Michele DeVries on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/28/2021: Step Mobile venture capital transaction
Next: 4/28/2021: Cigent Technology venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.